Diabetonorm Pioglitazone 15 Tablets

Diabetonorm Pioglitazone 15 Tablets

Description:

Diabetonorm Pioglitazone 45 mg 15 tablets is an oral antidiabetic prescription medicine used to improve blood sugar control in adults with type 2 diabetes mellitus. It belongs to the thiazolidinedione (TZD) class and acts as an insulin sensitizer, helping the body use its own insulin more effectively. Diabetonorm is typically used as an adjunct to diet and exercise, and may be prescribed alone or in combination with other antidiabetic medications such as metformin, sulfonylureas, or insulin. This product is designed for long-term glycemic control under medical supervision as part of a comprehensive diabetes care plan.

Indications:

• Type 2 diabetes mellitus in adults, particularly in patients with insulin resistance who require improved glycemic control.
• Reduction of elevated fasting and postprandial blood glucose levels when diet and exercise alone are insufficient.
• Improvement of long-term glycemic control as reflected by reduced HbA1c levels.
• May be used as monotherapy or in combination therapy with other oral antidiabetic agents or insulin, as prescribed by a physician.

Active Ingredients / Key Components:

• Pioglitazone hydrochloride – 45 mg per tablet (thiazolidinedione oral antidiabetic, insulin sensitizer).
• Excipients: Exact excipient list and concentrations , please check the product leaflet or the manufacturer’s official website. Refer to the official package insert for full inactive ingredient details.

Dosage & Administration / How to Use:

• Usual adult dose: The typical starting dose and maintenance dose are determined individually by the treating physician. For this strength, 45 mg once daily may be used in selected patients as directed by the doctor.
• Administration: Take the tablet orally once daily, at the same time each day, with or without food, with a sufficient amount of water. Do not crush or chew the tablet unless advised by your healthcare provider.
• Combination therapy: When used with other antidiabetic agents (e.g., metformin, sulfonylureas, or insulin), the doses of concomitant medications may need adjustment to reduce the risk of hypoglycemia, according to physician instructions.
• Duration of use: Diabetonorm is intended for long-term treatment. Do not stop taking the medication without consulting your doctor, even if you feel better or your blood sugar appears controlled.
• Missed dose: If you miss a dose, take it as soon as you remember on the same day. If it is almost time for your next dose, skip the missed dose and resume your regular schedule. Do not take a double dose to make up for a missed one.
• Monitoring: Regular monitoring of blood glucose, HbA1c, liver function tests, and body weight is recommended during therapy. Your doctor may also monitor for signs of fluid retention or heart failure.
• Use only under medical supervision and strictly follow your physician’s instructions regarding dose and duration.

Clinical Benefits:

• Improves insulin sensitivity in muscle and adipose tissue by acting as a selective agonist of PPAR-gamma, enhancing glucose uptake via GLUT4 transporters.
• Reduces hepatic gluconeogenesis, contributing to lower fasting blood glucose levels and better overall glycemic control.
• Lowers blood glucose and HbA1c, helping to reduce the risk of long-term diabetes complications when used as part of a comprehensive management plan.
• Decreases circulating insulin levels by improving insulin sensitivity, which may reduce the burden on pancreatic beta cells.
• Favorable effects on lipid profile: tends to raise HDL cholesterol and lower serum triglyceride levels, usually without significant change in LDL levels.
• Provides once-daily oral dosing, supporting better treatment adherence for adults managing type 2 diabetes.

Warnings & Contraindications:

• Contraindicated in patients with known hypersensitivity to pioglitazone or any component of the formulation.
• Contraindicated in patients with current or history of heart failure (especially NYHA Class III or IV) due to risk of fluid retention and worsening heart failure.
• Use with caution in patients with edema, cardiovascular disease, or risk factors for heart failure. Monitor for rapid weight gain, dyspnea, or swelling of the legs.
• Not recommended in patients with active liver disease or significantly elevated liver enzymes. Baseline and periodic liver function tests are advised.
• May cause or worsen fluid retention and edema, particularly when used with insulin. Dose adjustment or discontinuation may be required if heart failure develops.
• Use with caution in patients with bladder cancer history or unexplained hematuria; some data suggest a possible increased risk of bladder cancer with long-term high-dose use.
• May increase risk of bone fractures, especially in women. Advise patients about fall prevention and bone health.
• Hypoglycemia risk increases when combined with insulin or insulin secretagogues (e.g., sulfonylureas). Dose adjustments of concomitant drugs may be necessary.
• Pregnancy and breastfeeding: Use only if clearly needed and prescribed by a physician. Insulin is generally preferred during pregnancy. Consult your doctor before use if pregnant, planning pregnancy, or breastfeeding.
• Not indicated for type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
• Consult your doctor before use if you have liver disease, heart disease, edema, bladder problems, osteoporosis, or any serious chronic condition.
• Keep out of reach of children. Use only as prescribed and do not share this medication with others.
• This product is a prescription medicine and must be used under medical supervision.

Side Effects:

• Common side effects may include weight gain, fluid retention or edema (swelling of ankles or legs), headache, muscle pain, and mild upper respiratory symptoms.
• Gastrointestinal effects such as nausea, abdominal discomfort, or flatulence may occur in some patients.
• Increased risk of hypoglycemia when used in combination with insulin or sulfonylureas; symptoms include sweating, tremor, dizziness, palpitations, and confusion.
• Possible decrease in hemoglobin and hematocrit, usually mild.
• Serious side effects may include heart failure or worsening of existing heart failure (shortness of breath, sudden weight gain, swelling of legs), liver dysfunction (dark urine, jaundice, persistent nausea, fatigue), or signs of bladder problems (blood in urine, painful urination, urgent need to urinate).
• Increased risk of bone fractures, particularly in women, especially involving the distal upper and lower limbs.
• Allergic reactions are rare but may include rash, itching, swelling, severe dizziness, or difficulty breathing. Seek immediate medical attention if these occur.
• If you experience any unusual, persistent, or severe side effects, contact your doctor or pharmacist promptly.

Storage Instructions:

Store in a cool, dry place away from direct sunlight. Keep container tightly closed. Keep out of reach of children. Do not use after the expiry date printed on the pack. Store at or below the temperature recommended on the package insert (exact temperature range is not available in the provided information; refer to the official pack for details). Do not use if the blister is damaged or shows signs of tampering.

Specifications:

• Product type: Oral antidiabetic prescription medicine (insulin sensitizer).
• Strength: 45 mg pioglitazone per tablet.
• Form: Tablet.
• Pack size: 15 tablets per pack.
• Intended users: Adults with type 2 diabetes mellitus, as prescribed by a healthcare professional.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.